infliximab   

GtoPdb Ligand ID: 5004

Synonyms: cA2 | Inflectra® | Remicade® | Remsima® | SB2 | TA-650
infliximab is an approved drug (FDA (1998), EMA (1999))
Compound class: Antibody
Comment: Infliximab is an anti-tumour necrosis factor (TNF)α, mouse-human chimeric monoclonal antibody. It binds both soluble and transmembrane forms of TNFα but not lymphotoxin α (TNFβ).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Peptide sequence analysis reveals this to be antibody cA2 in patent US5656272 [5].

Biosimilars:
NameTrade nameCompanyClinical PhaseIndicationsReferences
infliximab-dyyb; CT-P13Remsima; Inflectra; FlammegisCelltrion/PfizerApproved (2013 EMA, 2016 FDA)As per reference agent[1-2,8]
infliximab-abda; SB2Flixabi; RenflexisMerck/SamsungBioepisApproved (2016 EMA, 2017 FDA)As per reference agent 
infliximab-qbtx; PF-06438179Ixifi; ZesslyPfizer?SandozApproved (2017 FDA, 2018 EMA)As per reference agent[3]
NI-071 Nichi-Iko PharmaceuticalApproved (2017 Japan); Phase 3 US (NCT02990806)As per reference agent 
BCD-055 BiocadPh 3 (NCT02762838)Rheumatoid arthritis 
Infliximab-EPIRUS; BOW015InfimabEpirus BiopharmaceuticalsApproved (2014 India); Ph 3 US (NCT02683564)Rheumatoid arthritis 
infliximab-axxq; ABP710AvsolaAmgenApproved (2019 FDA)As per reference agent 
STI-002 MabTech/Sorrento Therapeutic   
Infliximab biosimilar 1 Nippon KayakuApproved (Japan 2014)As per reference agent
Two more biosimilars have been approved in Japan: Infliximab biosimilar 2 (Nichi-Iko Pharmaceutical/ Yakuhan Pharmaceutical; 2017) and Infliximab biosimilar 3 (Pfizer Japan; 2018), both indicatated as per reference agent [4].
IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: infliximab

References
1. A-González N, Castrillo A. (2011)
Liver X receptors as regulators of macrophage inflammatory and metabolic pathways.
Biochim. Biophys. Acta, 1812 (8): 982-94. [PMID:21193033]
2. Blair HA, Deeks ED. (2016)
Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.
BioDrugs, 30 (5): 469-480. [PMID:27650650]
3. Derzi M, Johnson TR, Shoieb AM, Conlon HD, Sharpe P, Saati A, Koob S, Bolt MW, Lorello LG, McNally J et al.. (2016)
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade(®) (Infliximab).
Adv Ther, 33 (11): 1964-1982. [PMID:27585978]
4. Generics and Biosimilars Initiative. 
Biosimilars approved in Japan.
Accessed on 25/01/2019. Modified on 25/01/2019. gabionline.net, http://www.gabionline.net/Biosimilars/General/Biosimilars-approved-in-Japan
5. Le J, Vilcek J, Dadonna P, Ghrayeb J, Knight D, Siegel SA. (1997)
Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies.
Patent number: US5656272. Assignee: New York University Medical Center, Centocor, Inc.. Priority date: 18/03/1991. Publication date: 12/08/1997.
6. Rutgeerts P, D'Haens G, Targan S, Vasiliauskas E, Hanauer SB, Present DH, Mayer L, Van Hogezand RA, Braakman T, DeWoody KL et al.. (1999)
Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease.
Gastroenterology, 117 (4): 761-9. [PMID:10500056]
7. van Dullemen HM, van Deventer SJ, Hommes DW, Bijl HA, Jansen J, Tytgat GN, Woody J. (1995)
Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2).
Gastroenterology, 109 (1): 129-35. [PMID:7797011]
8. Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, Baranauskaite A, Wiland P, Abud-Mendoza C, Oparanov B et al.. (2017)
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study.
Ann. Rheum. Dis., 76 (2): 355-363. [PMID:27130908]